Angioplasty of Arteries of Lower Extremities for Peripheral Artery Disease - European Reimbursement Report

  • ID: 4250294
  • Report
  • Region: Europe
  • European Med Tech Reimbursement Consulting AB
1 of 4
Essential Information about Reimbursement and National Funding for Angioplasty

FEATURED COMPANIES

  • Abbott Vascular
  • Balton
  • BrosMed
  • Endocor
  • Lepu Medical
  • Optimed
  • MORE

This report presents a summary of the reimbursement situation in Europe for a group of angioplasty procedures of arteries of lower extremities for peripheral artery disease (plain and drug-eluting balloon angioplasty, stenting using bare metal and drug-eluting stents).

Analysis covers iliac, femoral and popliteal arteries.

Analysis is provided for admitted and day case hospital care.

The following clinical scenarios are considered:

  • Balloon angioplasty as stand-alone procedure
  • Balloon angioplasty using drug-eluting balloon
  • Balloon angioplasty in combination with percutaneous transluminal atherectomy
  • Balloon angioplasty in combination with insertion of stent
  • Insertion of bare metal stent
  • Insertion of drug-eluting stent

Report includes essential information about reimbursement and national funding for angioplasty, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following countries:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Vascular
  • Balton
  • BrosMed
  • Endocor
  • Lepu Medical
  • Optimed
  • MORE

1. Introduction and summary

2. Executive summary table
2.1. Percutaneous transluminal angioplasty with plain balloon
2.2. Percutaneous transluminal angioplasty with drug-eluting balloon
2.3. Percutaneous transluminal angioplasty with insertion of bare metal stent
2.4. Percutaneous transluminal angioplasty with insertion of drug-eluting stent

3. Contents

4. Methodology

5. Reimbursement analysis in Austria
5.1. Overview of the reimbursement system
5.2. Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
5.2.1. Procedure coding
5.2.2. Diagnosis coding
5.2.3. Payment mechanism and reimbursement tariffs
5.2.4. Health technology assessment by LBI-HTA
5.2.4.1. Percutaneous transluminal angioplasty with drug-eluting stent
5.2.4.2. Percutaneous transluminal angioplasty with drug-eluting balloon

6. Reimbursement analysis in Belgium
6.1. Overview of the reimbursement system
6.2. Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
6.2.1. Procedure coding
6.2.2. Material coding
6.2.3. Payment mechanism and reimbursement tariffs
6.2.4. Brand-specific reimbursement for drug-eluting stents and drug-coated balloons
6.2.5. Policy considerations
6.2.5.1. Reimbursement framework for percutaneous transluminal angioplasty with insertion of drug-eluting stent determined by INAMI
6.2.5.2. Reimbursement framework for percutaneous transluminal angioplasty with drug-eluting balloon determined by INAMI
6.2.5.3. Health technology assessment by Belgian Health Care Knowledge Centre

7. Reimbursement analysis in Denmark
7.1. Overview of the reimbursement system
7.2. Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
7.2.1. Procedure coding
7.2.2. Diagnosis coding
7.2.3. Payment mechanism and reimbursement tariffs

8. Reimbursement analysis in England
8.1. Overview of the reimbursement system
8.2. Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
8.2.1. Procedure coding
8.2.2. Diagnosis coding
8.2.3. Payment mechanism and reimbursement tariffs
8.2.4. Policy considerations
8.2.4.1. National commissioning of percutaneous transluminal angioplasty with or without stenting by NHS England
8.2.4.2. Health technology assessment of percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease by NICE
8.2.4.3. Clinical guideline for diagnosis and management of peripheral arterial disease by NICE

9. Reimbursement analysis in France
9.1. Overview of the reimbursement system
9.2. Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
9.2.1. Procedure coding
9.2.2. Diagnosis coding
9.2.3. Payment mechanism and reimbursement tariffs
9.2.4. Brand-specific reimbursement
9.2.5. Policy considerations
9.2.5.1. Drug-eluting balloons
9.2.5.2. Bare metal stents
9.2.5.3. Self-expanding drug-eluting stents

10. Reimbursement analysis in Germany
10.1. Overview of the reimbursement system
10.2. Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
10.2.1. Procedure coding
10.2.2. Diagnosis coding
10.2.3. Payment mechanism and reimbursement tariffs in hospital setting
10.2.4. Payment mechanism and reimbursement tariffs in day case
10.2.5. Policy considerations

11. Reimbursement analysis in Italy
11.1. Overview of the reimbursement system
11.2. Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
11.2.1. Procedure coding
11.2.2. Diagnosis coding
11.2.3. Payment mechanism and reimbursement tariffs at national level
11.2.4. Payment mechanism and reimbursement tariffs at regional level

12. Reimbursement analysis in the Netherlands
12.1. Overview of the reimbursement system
12.2. Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
12.2.1. Procedure coding
12.2.1.1. Procedure coding for intervention performed by surgeon
12.2.1.2. Procedure coding for interventions performed by radiologist
12.2.2. Material coding
12.2.3. Diagnosis coding
12.2.4. Payment mechanism and reimbursement tariffs
12.2.4.1. Payment mechanism and reimbursement tariffs for interventions performed by surgeon
12.2.4.2. Payment mechanism and reimbursement tariffs for interventions performed by radiologist
12.2.5. Policy considerations
12.2.6. Health technology assessment by National Healthcare Institute

13. Reimbursement analysis in Norway
13.1. Overview of the reimbursement system
13.2. Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
13.2.1. Procedure coding
13.2.2. Diagnosis coding
13.2.3. Payment mechanism and reimbursement tariffs in hospital setting
13.2.4. Payment mechanism and reimbursement tariffs in day case
13.2.5. Policy considerations
13.2.5.1. Assessment within national framework of managed introduction of innovations

14. Reimbursement analysis in Sweden
14.1. Overview of the reimbursement system
14.2. Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
14.2.1. Procedure coding
14.2.2. Diagnosis coding
14.2.3. Payment mechanism and reimbursement tariffs in hospital setting
14.2.4. Payment mechanism and reimbursement tariffs in day case
14.2.5. Policy considerations
14.2.5.1. Swedish Drug-elution Trial in Peripheral Arterial Disease trial (SWEDEPAD)

15. Reimbursement analysis in Switzerland
15.1. Overview of the reimbursement system
15.2. Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
15.2.1. Procedure coding
15.2.2. Diagnosis coding
15.2.3. Payment mechanism and reimbursement tariffs in hospital setting
15.2.4. Payment mechanism and reimbursement tariffs in day case
15.2.5. Policy considerations

16. Disclaimer

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AMG International
  • Aachen Resonance (ELUTAX SV)
  • Abbott Vascular
  • Alvimedica
  • Andramed
  • Angiodynamics
  • B Braun
  • Balton
  • Bard / Lutonix (LUTONIX Drug Coated Balloon Catheter)
  • Bentley InnoMed
  • Biosensors International
  • Biotronik
  • Boston Scientific
  • BostonScientific (Ranger)
  • BrosMed
  • CR Bard
  • Cardionovum (Legflow)
  • Cook Medical
  • Cordis
  • Degania Silicone
  • Endocor
  • Eucatech
  • Eurocor Endovascular (Freeway)
  • Hexacath
  • IVascular
  • InSitu Technologies
  • Jotec
  • Lepu Medical
  • Medinol
  • Medtronic
  • Meril
  • Merit Medical
  • MicroPort
  • Optimed
  • QTVascular
  • Rontis
  • Spectranetics
  • Stentys
  • Stron Medical
  • Terumo
  • Vascular Concepts
  • Veryan
  • W.L. Gore
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll